Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
Femasys Inc. (NASDAQ: FEMY) has announced a strategic partnership with Medical Electronic Systems LLC (MES) to launch the FemSperm Analysis Kit. This addition completes the FemSperm product family, which includes the Setup Kit and Insemination Prep Kit.
The partnership enables gynecologists to perform complete in-office sperm preparation and analysis for FemaSeed Intratubal Insemination, a first-step infertility treatment. FemaSeed has demonstrated more than double the pregnancy rates of intrauterine insemination (IUI) in cases of low male sperm count in its pivotal trial.
The solution is currently authorized for use in multiple markets including the U.S., Europe, UK, Canada, Israel, Australia and New Zealand, offering a more accessible and cost-effective alternative to traditional fertility treatments.
Femasys Inc. (NASDAQ: FEMY) ha annunciato una partnership strategica con Medical Electronic Systems LLC (MES) per lanciare il FemSperm Analysis Kit. Questa aggiunta completa la famiglia di prodotti FemSperm, che include il Setup Kit e l'Insemination Prep Kit.
La partnership permette alle ginecologhe di eseguire una preparazione e analisi dello sperma in ambulatorio per la FemaSeed Inseminazione Intratubare, un primo passo nel trattamento dell'infertilità. FemaSeed ha dimostrato tassi di gravidanza più che raddoppiati rispetto all'inseminazione intrauterina (IUI) nel proprio trial fondamentale, soprattutto in casi di basso conteggio spermatozoo maschile.
La soluzione è attualmente autorizzata per l'uso in diversi mercati, tra cui USA, Europa, Regno Unito, Canada, Israele, Australia e Nuova Zelanda, offrendo un'alternativa più accessibile ed economica ai trattamenti di fertilità tradizionali.
Femasys Inc. (NASDAQ: FEMY) ha anunciado una alianza estratégica con Medical Electronic Systems LLC (MES) para lanzar el FemSperm Analysis Kit. Esta incorporación completa la familia de productos FemSperm, que incluye el Setup Kit y el Insemination Prep Kit.
La asociación permite a los ginecólogos realizar una preparación y análisis de esperma in situ para la Inseminación Intratubárica FemaSeed, un primer paso en el tratamiento de la infertilidad. FemaSeed ha demostrado tasas de embarazo más que duplicadas en relación con la inseminación intrauterina (IUI) en su ensayo pivotal, especialmente en casos de recuento bajo de espermatozoides masculinos.
La solución está actualmente autorizada para su uso en múltiples mercados, incluyendo EE. UU., Europa, Reino Unido, Canadá, Israel, Australia y Nueva Zelanda, ofreciendo una alternativa más accesible y rentable a los tratamientos de fertilidad tradicionales.
Femasys Inc. (NASDAQ: FEMY)가 Medical Electronic Systems LLC(MES)와 전략적 파트너십을 발표하여 FemSperm Analysis Kit를 출시합니다. 이 추가로 FemSperm 제품군이 완성되며, 여기에는 Setup Kit와 Insemination Prep Kit이 포함됩니다.
파트너십을 통해 산부인과 의사는 FemaSeed 관관 난자 투입(Intra-tubal) 인세미네이션을 위한 사무실 내 정액 준비 및 분석을 수행할 수 있게 되며, 이는 최초의 불임 치료 단계입니다. FemaSeed는 기초 연구에서 낮은 남성 정자 수의 경우 자궁 내 인공 수정(IUI)에 비해 임신율이 두 배 이상 증가하는 것을 입증했습니다.
현재 이 솔루션은 미국, 유럽, 영국, 캐나다, 이스라엘, 호주 및 뉴질랜드를 포함한 여러 시장에서 사용이 인가되어 있어, 전통적인 불임 치료에 비해 더 접근 가능하고 비용 효율적인 대안을 제공합니다.
Femasys Inc. (NASDAQ: FEMY) a annoncé un partenariat stratégique avec Medical Electronic Systems LLC (MES) pour lancer le FemSperm Analysis Kit. Cette nouvelle complète la famille de produits FemSperm, qui comprend le Setup Kit et le Insemination Prep Kit.
Le partenariat permet aux gynécologues d’effectuer une préparation et analyse du sperme en cabinet pour l’insemination intratubaire FemaSeed, une étape précoce du traitement de l’infertilité. FemaSeed a démontré des taux de grossesse plus que doublés par rapport à l’insémination intra-utérine (IUI) dans son essai pivot, notamment dans les cas de faible compte de spermatozoïdes masculins.
La solution est actuellement autorisée pour une utilisation dans plusieurs marchés, notamment aux États-Unis, en Europe, au Royaume-Uni, au Canada, en Israël, en Australie et en Nouvelle-Zélande, offrant une alternative plus accessible et économique aux traitements de fertilité traditionnels.
Femasys Inc. (NASDAQ: FEMY) hat eine strategische Partnerschaft mit Medical Electronic Systems LLC (MES) angekündigt, um das FemSperm Analysis Kit auf den Markt zu bringen. Diese Ergänzung vervollständigt die FemSperm-Produktfamilie, zu der das Setup Kit und das Insemination Prep Kit gehören.
Die Partnerschaft ermöglicht es Gynäkologen, eine in‑office Spermienaufbereitung und -analyse für die FemaSeed Intratubaren-Insemination durchzuführen, eine erste Behandlungsschritte bei Unfruchtbarkeit. FemaSeed hat in der entscheidenden Studie mehr als das Doppelte an Schwangerschaftsraten im Vergleich zur intrauterinen Insemination (IUI) bei Fällen mit niedrigem männlichen Spermienkonzentration gezeigt.
Die Lösung ist derzeit in mehreren Märkten autoriziert, darunter USA, Europa, Großbritannien, Kanada, Israel, Australien und Neuseeland, und bietet eine zugänglichere und kostengünstigere Alternative zu herkömmlichen Fruchtbarkeitsbehandlungen.
Femasys Inc. (NASDAQ: FEMY) أعلنت عن شراكة استراتيجية مع Medical Electronic Systems LLC (MES) لإطلاق عينة فحص FemSperm Analysis Kit. يكتمل بهذا إضافة عائلة منتجات FemSperm، التي تشمل مجموعة الإعداد Setup Kit و Insemination Prep Kit.
تمكن الشراكة أخصائيي النساء من إجراء تحضير وتحليل السائل المنوي في العيادة لـ FemaSeed Intratubal Insemination، وهي خطوة أولى في علاج العقم. أظهرت FemaSeed معدلات حمل مضاعفة تقريباً مقارنةً بالتلقيح الاصطناعي داخل الرحم (IUI) في تجربتها الحيوية خصوصاً في حالات انخفاض عدد الحيوانات المنوية لدى الذكور.
الحل مُخول حالياً للاستخدام في عدة أسواق بما في ذلك الولايات المتحدة، أوروبا، المملكة المتحدة، كندا، إسرائيل، أستراليا ونيوزيلندا، مقدماً بديلاً أكثر وصولاً وتكلفة أقل من العلاجات التقليدية للعقم.
Femasys Inc. (NASDAQ: FEMY) 已宣布与 Medical Electronic Systems LLC (MES) 建立战略伙伴关系，推出 FemSperm Analysis Kit。此举完善了 FemSperm 产品家族，包含 Setup Kit 与 Insemination Prep Kit。
该合作使妇科医生能够在诊所内完成 精子制备与分析，用于 FemaSeed 输卵管内受精（Intratubal Insemination），这是不孕治疗的第一步。FemaSeed 在其核心试验中显示在低男性精子计数的情况下，其妊娠率 比宫内授精（IUI）高出一倍以上。
该方案目前已获多地授权使用，包括 美国、欧洲、英国、加拿大、以色列、澳大利亚和新西兰，为传统生育治疗提供了更易获得且成本更低的替代方案。
- Partnership with MES brings advanced sperm analysis technology to gynecologist offices
- FemaSeed showed double the pregnancy rates compared to IUI in low sperm count cases
- Expanded market access with authorization in multiple major markets
- Solution provides more affordable and accessible fertility treatment option
- None.
Insights
Femasys expands fertility offerings with FemSperm Analysis Kit, enabling gynecologists to provide complete in-office fertility treatments with stronger clinical results than alternatives.
Femasys has strategically expanded its fertility product ecosystem through a new partnership with Medical Electronic Systems (MES), launching the FemSperm Analysis Kit to complete its FemSperm product family. This addition transforms Femasys' offering from individual products into a comprehensive fertility solution that brings advanced reproductive care directly to gynecologists' offices – a significant market expansion beyond traditional fertility clinics.
The FemSperm product family now includes three integrated components: the Setup Kit, Insemination Prep Kit, and the newly added Analysis Kit. Together, they enable gynecologists to perform the complete FemaSeed Intratubal Insemination procedure in-office, from sperm preparation through delivery. This positions Femasys to capture more value from each procedure while expanding the addressable market for its technology.
Particularly compelling is the clinical data mentioned: FemaSeed demonstrated more than double the pregnancy rates of intrauterine insemination (IUI) in cases with low male sperm count. This positions FemaSeed as both medically superior and more accessible than current options, creating a strong value proposition for both providers and patients.
The partnership with MES, an established leader in sperm analysis technology, also brings credibility and technical expertise to Femasys' solution. By integrating MES technology under its own brand umbrella, Femasys maintains control of the customer relationship while leveraging specialized technology.
With regulatory approvals already secured across major markets including the US, Europe, UK, Canada, Israel, Australia, and New Zealand, Femasys has positioned itself to rapidly commercialize this expanded solution across global markets, potentially accelerating revenue growth through both deeper market penetration and geographic expansion.
Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal Insemination
ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Medical Electronic Systems LLC (MES) to provide advanced sperm analysis technology. The FemSperm Analysis Kit completes the FemSperm product family, joining the Setup Kit and Insemination Prep Kit. Together, they expand Femasys’ infertility portfolio and, for the first time, enables gynecologists to perform in-office sperm preparation and analysis for use with its first-step infertility treatment, FemaSeed Intratubal Insemination.
“The launch of the FemSperm Analysis Kit advances our mission to deliver innovative reproductive care that is more accessible and affordable for the millions of women facing infertility,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “By partnering with MES, a recognized leader in sperm analysis technology, and branding their advanced solution under our FemSperm product line, we have created a complete, turnkey offering that empowers gynecologists to provide FemaSeed in-office infertility treatment previously available only in fertility clinics.”
“Our industry-leading semen analysis technology powers the FemSperm Analysis Kit, delivering accurate, efficient, and standardized assessment of key sperm parameters,” said Eric Carver, President of Medical Electronic Systems LLC. “We are thrilled to partner with Femasys to bring our technology to gynecologists as part of a complete, integrated solution that expands access to high-quality infertility care.”
With the availability of the FemSperm product family, gynecologists can now perform sperm preparation and analysis, enabling them to offer FemaSeed Intratubal Insemination directly within their practices. FemaSeed is a next-generation artificial insemination solution that enhances natural fertilization by delivering sperm precisely to the fallopian tube, the site of conception. Positioned as a true first step in the fertility journey, FemaSeed offers a safe, accessible, and cost-effective alternative to intrauterine insemination (IUI). In its pivotal trial, FemaSeed achieved more than double the pregnancy rates of IUI in cases of low male sperm count.1 As an affordable, less invasive, lower-risk option before IVF, FemaSeed is authorized for use in the U.S., Europe, UK, Canada, Israel, Australia and New Zealand. Learn more at www.femaseed.com.
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, United Kingdom in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
About Medical Electronic Systems LLC (MES)
Medical Electronic Systems (MES) is a global leader in automated semen analysis solutions, providing advanced equipment to fertility clinics, hospitals, and laboratories worldwide. MES technologies are designed to deliver accurate, efficient, and standardized results in sperm analysis. MES is recognized for introducing the first FDA- and CE-cleared, at-home semen analysis solution, the smartphone-based YO® Home Sperm Test, bringing laboratory-grade accuracy to consumers and expanding access to male fertility testing. More information on MES can be found at www.mes-global.com.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
FAQ
What is the new FemSperm Analysis Kit announced by Femasys (NASDAQ: FEMY)?
How does FemaSeed compare to traditional intrauterine insemination (IUI)?
Where is Femasys's FemaSeed treatment currently authorized for use?
What products are included in the complete FemSperm family by Femasys?
How does the Femasys and MES partnership benefit gynecologists?
